Difficulty: Medium
Average Score: 71%
Practice
The MOST vital initial treatment in the management of severe asthma exacerbations is
Correct answer
B
Rationale
In the management of severe asthma exacerbations in pediatric patients, the MOST vital initial treatment is the administration of inhaled B-agonists. This is the correct answer (option B) because B-agonists, such as albuterol, work by quickly relaxing the airway smooth muscles, providing rapid relief of bronchospasm and improving airflow. This is crucial in managing acute asthma attacks and preventing respiratory failure.
Supplemental oxygen (option A) may be necessary for patients with severe asthma exacerbations, but it is not the MOST vital initial treatment. Oxygen therapy is usually provided alongside bronchodilators like B-agonists.
Intramuscular injection of epinephrine (option C) is not recommended as a first-line treatment for severe asthma exacerbations in children. Epinephrine is primarily used in managing anaphylaxis, not asthma.
Inhaled ipratropium (option D) is another bronchodilator that can be used in conjunction with B-agonists in the treatment of asthma exacerbations, but it is not the MOST vital initial treatment. B-agonists are preferred due to their rapid onset of action and effectiveness in relieving bronchospasm.
Educationally, it is essential for pediatric nurses to understand the priority interventions in managing acute asthma exacerbations to provide timely and effective care. By recognizing the importance of inhaled B-agonists as the initial treatment, nurses can help stabilize pediatric patients experiencing severe asthma attacks and prevent further respiratory compromise. Understanding the rationale behind treatment choices is crucial for delivering safe and evidence-based pediatric care.
Supplemental oxygen (option A) may be necessary for patients with severe asthma exacerbations, but it is not the MOST vital initial treatment. Oxygen therapy is usually provided alongside bronchodilators like B-agonists.
Intramuscular injection of epinephrine (option C) is not recommended as a first-line treatment for severe asthma exacerbations in children. Epinephrine is primarily used in managing anaphylaxis, not asthma.
Inhaled ipratropium (option D) is another bronchodilator that can be used in conjunction with B-agonists in the treatment of asthma exacerbations, but it is not the MOST vital initial treatment. B-agonists are preferred due to their rapid onset of action and effectiveness in relieving bronchospasm.
Educationally, it is essential for pediatric nurses to understand the priority interventions in managing acute asthma exacerbations to provide timely and effective care. By recognizing the importance of inhaled B-agonists as the initial treatment, nurses can help stabilize pediatric patients experiencing severe asthma attacks and prevent further respiratory compromise. Understanding the rationale behind treatment choices is crucial for delivering safe and evidence-based pediatric care.